Evidence map›Paper›PMID 40396997›Full record

ReviewEuropean heart journal. Cardiovascular pharmacotherapy2025

Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus.

Susanne Kaser, Dobromir Dobrev, Bianca Rocca, Juan Carlos Kaski, Stefan Agewall, Heinz Drexel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Susanne KaserDepartment of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Dobromir DobrevInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, 45122 Essen, Germany.ORCID 0000-0002-4612-117X
Bianca RoccaDepartment of Medicine, LUM University, 70010 Casamassima (BA), Italy.ORCID 0000-0001-8304-6423
Juan Carlos KaskiDivision of Cardiovascular Medicine, Molecular and Clinical Sciences Research Institute, St George's University of London, SW17 0RE London, UK.
Stefan AgewallInstitute of Clinical Sciences, Karolinska Institute of Danderyd, 171 77 Stockholm, Sweden.
Heinz DrexelVorarlberg Institute for Vascular Investigation & Treatment (VIVIT) at the Academic Teaching Hospital Feldkirch, Carinagasse 47, 6800 Feldkirch, Austria.ORCID 0000-0002-4677-9756

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes is associated with excess cardiovascular risk. In contrast to type 2 diabetes, however, age at the onset of type 1 diabetes and sex are major predictors of cardiovascular risk, while the role of low-density lipoprotein cholesterol (LDL-C) and lipid-lowering therapy is less clear. Since most data on the effects of lipid-lowering treatments are obtained from randomized clinical trials that included very predominantly patients with type 2 diabetes, it is almost impossible to specifically discern endpoints in type 1 diabetes. Inversely, most data specific for type 1 diabetes are obtained from real world findings. Consequently, the evidence on efficacy and safety of lipid-lowering therapies available from randomized clinical trials arises very predominantly from type 2 diabetes. Thus, this specific review summarizes the evidence of lipid-lowering drug classes in reducing cardiovascular risk in patients with type 1 diabetes.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 1DyslipidemiasHypolipidemic AgentsLipidsBiomarkersComorbidityHumansRisk AssessmentRisk FactorsTreatment OutcomeBiomarkersHypolipidemic AgentsLipidsCardiovascular riskComorbiditiesDyslipidaemiaLipid lowering drugsRandomized clinical trialsType 1 diabetes mellitus

Identifiers

PMID40396997
PMCPMC12231131

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.